The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Real success is about taking control, gaining confidence, and achieving the energy to live life to the full, not simply shedding kilos.

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

The mechanisms driving the cardiovascular and renal benefits of therapies targeting intestinal hormones in type 2 diabetes ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

When we feed the body correctly, we can influence the same systems that drugs like Mounjaro target - helping regulate appetite, reduce cravings and improve metabolic health.

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...